UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

_____________________

Form 8-K/A

(Amendment No. 1)

_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event Reported): August 26, 2021  

ACASTI PHARMA INC.

(Exact Name of Registrant as Specified in Charter)

450-686-4555

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

Explanatory Note.

This Form 8-K/A amends the Current Report on Form 8-K filed by Acasti Pharma Inc. ("Acasti") with the Securities and Exchange Commission (“SEC”) on August 27, 2021 (the "Original 8-K"), announcing the completion of its acquisition of Grace Therapeutics Inc. This Form 8-K/A amends the Original 8-K to include the financial statements required by Item 9.01.

Item 9.01. Financial Statements and Exhibits.

(a)       Financial statements of businesses acquired.

The financial statements required by this Item with respect to the Merger described in Item 2.01 in the Original 8-K, as modified hereby, were previously filed as part of as part of the Registration Statement on Form S-4 filed by Acasti with the SEC on June 30, 2021, as amended by Amendment no. 1 thereto filed with the SEC on July 13, 2021, link to which is found in Exhibit 99.1 hereto.

(b)       Pro forma financial information.

The pro forma financial information required by this Item with respect to the Merger described in Item 2.01 in the Original 8-K, as modified hereby, were previously filed as part of the Registration Statement on Form S-4 filed by Acasti with the SEC on June 30, 2021, as amended by Amendment no. 1 thereto filed with the SEC on July 13, 2021, a link to which is found in Exhibit 99.2 hereto.

(d)        Exhibits.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.